Your browser doesn't support javascript.
loading
Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
Vallejos, Rodrigo; Zhantuyakova, Almira; Negri, Gian Luca; Martin, Spencer D; Spencer, Sandra E; Thornton, Shelby; Leung, Samuel; Lynch, Branden; Qin, Yimei; Chow, Christine; Liang, Brooke; Zdravko, Sabrina; Douglas, J Maxwell; Milne, Katy; Mateyko, Bridget; Nelson, Brad H; Howitt, Brooke E; Kommoss, Felix Kf; Horn, Lars-Christian; Hoang, Lien; Singh, Naveena; Morin, Gregg B; Huntsman, David G; Cochrane, Dawn.
Affiliation
  • Vallejos R; Department of Genome Sciences and Technology, University of British Columbia, Vancouver, BC, Canada.
  • Zhantuyakova A; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Negri GL; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Martin SD; Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada.
  • Spencer SE; Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Thornton S; Diagnostic and Molecular Pathology, University of British Columbia, Vancouver, BC, Canada.
  • Leung S; Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Lynch B; Molecular and Advanced Pathology Core, University of British Columbia, Vancouver, BC, Canada.
  • Qin Y; Molecular and Advanced Pathology Core, University of British Columbia, Vancouver, BC, Canada.
  • Chow C; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Liang B; Molecular and Advanced Pathology Core, University of British Columbia, Vancouver, BC, Canada.
  • Zdravko S; Molecular and Advanced Pathology Core, University of British Columbia, Vancouver, BC, Canada.
  • Douglas JM; Stanford University School of Medicine, Stanford, CA, USA.
  • Milne K; Stanford University School of Medicine, Stanford, CA, USA.
  • Mateyko B; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Nelson BH; Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Howitt BE; Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Kommoss FK; Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Horn LC; Stanford University School of Medicine, Stanford, CA, USA.
  • Hoang L; Department of Molecular Oncology, BC Cancer, Vancouver, BC, Canada.
  • Singh N; Diagnostic and Molecular Pathology, University of British Columbia, Vancouver, BC, Canada.
  • Morin GB; Division of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.
  • Huntsman DG; Diagnostic and Molecular Pathology, University of British Columbia, Vancouver, BC, Canada.
  • Cochrane D; Diagnostic and Molecular Pathology, University of British Columbia, Vancouver, BC, Canada.
J Pathol ; 264(2): 197-211, 2024 Oct.
Article in En | MEDLINE | ID: mdl-39081243
ABSTRACT
Low-grade serous ovarian carcinoma (LGSC) is a rare and lethal subtype of ovarian cancer. LGSC is pathologically, biologically, and clinically distinct from the more common high-grade serous ovarian carcinoma (HGSC). LGSC arises from serous borderline ovarian tumours (SBTs). The mechanism of transformation for SBTs to LGSC remains poorly understood. To better understand the biology of LGSC, we performed whole proteome profiling of formalin-fixed, paraffin-embedded tissue blocks of LGSC (n = 11), HGSC (n = 19), and SBTs (n = 26). We identified that the whole proteome is able to distinguish between histotypes of the ovarian epithelial tumours. Proteins associated with the tumour microenvironment were differentially expressed between LGSC and SBTs. Fibroblast activation protein (FAP), a protein expressed in cancer-associated fibroblasts, is the most differentially abundant protein in LGSC compared with SBT. Multiplex immunohistochemistry (IHC) for immune markers (CD20, CD79a, CD3, CD8, and CD68) was performed to determine the presence of B cells, T cells, and macrophages. The LGSC FAP+ stroma was associated with greater abundance of Tregs and M2 macrophages, features not present in SBTs. Our proteomics cohort reveals that there are changes in the tumour microenvironment in LGSC compared with its putative precursor lesion, SBT. These changes suggest that the tumour microenvironment provides a supportive environment for LGSC tumourigenesis and progression. Thus, targeting the tumour microenvironment of LGSC may be a viable therapeutic strategy. © 2024 The Pathological Society of Great Britain and Ireland.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous / Tumor Microenvironment Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Pathol Year: 2024 Type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenocarcinoma, Serous / Tumor Microenvironment Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Pathol Year: 2024 Type: Article Affiliation country: Canada